NEEDHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for oral presentation in the Practice-changing, Paradigm-shifting Clinical Trials in Urology session, as part of the American Urological Association (AUA) 2026 Annual Meeting Plenary Program being held in Washington D.C. from May 15-18, 2026. The presentation will feature new data from the Company's phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with intermediate- to high-risk localized prostate cancer.Presentation Details: Aglatimagene – Localized Prostate CancerAbstract Title: Extended follow-up shows accumulating benefit for patients treated with CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) in men with localized prostate cancer: update from PrTK03 randomized phase 3 clinical trialPresentation Type: PlenaryPresenter: Mark G. Garzotto, M.D., Professor of Urology and Radiation Medicine, Oregon Health & Science University, Chief, Urology Section, Portland VA Medical CenterSession Title: P2s: Practice-changing, Paradigm-shifting Clinical Trials in UrologySession Date/Time: Friday, May 15, 2026; 11:30 AM - 11:40 AM ETLocation: Hall D, Walter E. Washington Convention Center, Washington, D.C.Full abstracts will be released by AUA on date and time of presentation. Details from the presentation will be available following the event on the Candel website at https://www.candeltx.com/media/.About Candel TherapeuticsCandel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (aglatimagene or CAN-2409) is the ...Full story available on Benzinga.com